Director, Health Economics & Outcomes Research (HEOR)

About this role

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of underserved patients. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients. For more information, visit www.azurity.com.

Azurity Pharmaceuticals is proud to be an inclusive workplace and an Equal Opportunity Employer. Azurity's success is attributable to our incredibly talented, dedicated team that focuses on benefiting the lives of patients by bringing the best science and commitment to quality into everything that we do. We seek highly motivated individuals with the dedication, integrity, and creative spirit needed to thrive in our organization.

About the Role

Azurity Pharmaceuticals is a privately held specialty pharmaceutical company focused on innovative products that meet the needs of underserved patients. Within the Surgical Business Unit — our hospital-focused, targeted-delivery specialty business — we are building the value-evidence foundation for a portfolio of hospital and institutional products, beginning with D-PLEX100, a locally administered, extended-release surgical anti-infective for the prevention of surgical site infection.

We are seeking a Director, Health Economics & Outcomes Research (HEOR) to develop the HEOR evidence, economic models, and value dossiers that support access and reimbursement in the US and Canada. Reporting to the VP, Market Access & Strategic Accounts, this individual owns the value-evidence strategy and deliverables — starting with D-PLEX100 and extending to future assets — and translates clinical and economic data into the tools that hospital, payer, and health-technology-assessment decision-makers require.

The HEOR Director builds the budget-impact and cost-effectiveness evidence that underpins DRG economics, the New Technology Add-On Payment (NTAP) application, hospital coding strategy, and the P&T and value-analysis-committee value story. The role partners closely with Market Access, Medical Affairs, Brand Marketing, the field organization, Regulatory, and Program Management, and manages external HEOR vendors and academic collaborators.

The ideal candidate brings a minimum of 8 years of HEOR, health economics, or value & access experience in pharmaceutical, biotech, or device, including dossier and economic-model development and US reimbursement strategy. Hospital / inpatient, anti-infective, surgical, or device experience and familiarity with both US and Canadian access environments are strongly preferred.

Key Responsibilities

Value Evidence Strategy

• Own the HEOR and value-evidence strategy for the Surgical Business Unit, beginning with D-PLEX100, and build the integrated evidence plan that supports US and Canadian access and reimbursement across the product lifecycle.

• Identify evidence gaps against the requirements of hospital decision-makers, payers, and health-technology-assessment (HTA) bodies, and prioritize the studies and analyses needed to close them.

• Define the economic value proposition for an inpatient, DRG-reimbursed surgical product, and align it with brand strategy and market-access objectives.

Dossiers, Models & Deliverables

• Lead development of value dossiers — including the AMCP dossier — and the supporting clinical and economic evidence summaries.

• Build and maintain budget-impact and cost-effectiveness models, cost-of-care and cost-offset analyses (e.g., the economic burden of surgical site infection), and account-level value calculators for institutional customers.

• Develop payer, hospital, and P&T / value-analysis-committee value tools and objection-handling materials, and equip the field and account teams with compliant value narratives.

Reimbursement, NTAP & Coding

• Lead the health-economic and evidence components of the New Technology Add-On Payment (NTAP) application and other inpatient add-on payment pathways, in partnership with Market Access and Program Management.

• Develop the hospital coding and reimbursement strategy — MS-DRG mapping, HCPCS/ICD coding, and the economic case for appropriate reimbursement — and produce supporting materials for hospital finance and revenue-cycle stakeholders.

• Model DRG economics and the payment landscape so pricing, contracting, and the value story reflect how the product is actually reimbursed in the inpatient setting.

Evidence Generation & Publication

• Design and oversee HEOR studies — retrospective database, real-world evidence, chart review, and pragmatic analyses — using claims, EHR, and registry data, executed with internal teams and external vendors.

• Collaborate with clinical, biostatistics, and evidence-generation colleagues on outcomes endpoints and real-world evidence, and with KOLs on study design and authorship.

• Drive the HEOR publication and communication plan — abstracts, posters, and manuscripts for congresses such as ISPOR, AMCP, and IDWeek — to make the evidence available to decision-makers.

US & Canada Access Support

• Support US field engagement with payers, hospital systems, IDNs, and population-health decision-makers, providing compliant health-economic evidence and training.

• Develop the Canadian value-evidence and HTA strategy — CDA-AMC (formerly CADTH) and INESSS submissions, pan-Canadian considerations, and hospital / provincial access requirements — as D-PLEX100 advances in Canada.

• Monitor evolving evidence requirements, HTA methods, and ICER-type assessments, and prepare responses.

Measures of Success

• Evidence readiness: the AMCP dossier, budget-impact model, and core value tools are complete,…